Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Miranda Weggeman | F | - |
Fibriant BV
 Fibriant BV Pharmaceuticals: OtherHealth Technology Fibriant BV is a Dutch biotechnology company that specializes in the recombinant manufacturing and characterization of specific variants of human Fibrinogen and active human Thrombin. The company is based in Leiden, the Netherlands. The company's science and technology are centered around Fibrinogen, a soluble blood protein that can be converted into an insoluble three-dimensional Fibrin network. Fibriant captures the unique features and functions of specific recombinant variants of Fibrinogen in new innovative products and in improvements of existing products based on plasma Fibrinogen. The company was founded in 2015 by Jaap Koopman, Jos Grimbergen, Miranda Weggeman, and Jaap Koopman has been the CEO since then. | 9 years |
| Jos Grimbergen | M | - |
Fibriant BV
Fibriant BV Pharmaceuticals: OtherHealth Technology Fibriant BV is a Dutch biotechnology company that specializes in the recombinant manufacturing and characterization of specific variants of human Fibrinogen and active human Thrombin. The company is based in Leiden, the Netherlands. The company's science and technology are centered around Fibrinogen, a soluble blood protein that can be converted into an insoluble three-dimensional Fibrin network. Fibriant captures the unique features and functions of specific recombinant variants of Fibrinogen in new innovative products and in improvements of existing products based on plasma Fibrinogen. The company was founded in 2015 by Jaap Koopman, Jos Grimbergen, Miranda Weggeman, and Jaap Koopman has been the CEO since then. | 9 years |
| Domenico Valerio | M | 67 |
University of Leiden
| 32 years |
| Alain Parthoens | M | 64 |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | 13 years |
| Martijn Meijer | M | - |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jan Öhrström | M | 67 |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | - |
| Thessa Mooij | F | - |
University of Leiden
| 6 years |
| Vincent de Dorlodot | M | 59 |
University of Leiden
| 1 years |
| Jan Alexander Pruijs | M | - |
University of Leiden
| 3 years |
| Henk Tissing | M | - |
University of Leiden
| 4 years |
| Antoine Oijen | M | - |
University of Leiden
| 6 years |
| Hanno Cappon | M | 57 |
University of Leiden
| 3 years |
| Jie Weng | M | 61 |
University of Leiden
| 3 years |
| Mariëlle L. J. Paul | F | 57 |
University of Leiden
| 6 years |
| Peter Quaedflieg | M | - |
University of Leiden
| 3 years |
| Nebahat Albayrak | F | 56 |
University of Leiden
| 3 years |
| Maarten Kraan | M | 63 |
University of Leiden
| 7 years |
| Guido van Nispen | M | 59 |
University of Leiden
| 6 years |
| Ton Adang | M | 63 |
University of Leiden
| 3 years |
| Robert van Zwieten | M | 62 |
University of Leiden
| 11 years |
| Adriaan Stoop | M | 54 |
University of Leiden
| 3 years |
| Alain R. de Jonge | M | - |
University of Leiden
| 3 years |
| Linda Zuckerman | M | - |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | 3 years |
| Pieter Wolters | M | - |
University of Leiden
| 4 years |
| Leonard Kruimer | M | 66 |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | 2 years |
| Markus S. Meijer | M | - |
University of Leiden
| 3 years |
| Hank Boot | M | 56 |
University of Leiden
| 3 years |
| Francis J. Pinto | M | 82 | 7 years | |
| Robertus Lindner | M | 60 |
University of Leiden
| 2 years |
| Pan Jian Li | M | 61 |
University of Leiden
| 3 years |
| Joost de Bruijn | M | 58 |
University of Leiden
| 3 years |
| Stefan van den Eijnde | M | - |
University of Leiden
| 1 years |
| Wim H. Heijting | M | - |
University of Leiden
| 3 years |
| Ralph Sytze Ybema | M | 57 |
University of Leiden
| 3 years |
| Georgius J. M. Hersbach | M | 70 | 9 years | |
| Joost Holleman | M | - |
University of Leiden
| 6 years |
| Francesco de Rubertis | M | 54 |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | - |
| Joost Hessel Louis Bergsma | M | 59 |
University of Leiden
| 6 years |
| Mark Sanor | M | - |
University of Leiden
| - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Netherlands | 39 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jaap Koopman
- Personal Network
